Ads
related to: acute myeloid leukemia news- About FLT3m+ AML
Review Information on FLT3 Mutation
Positive Acute Myeloid Leukemia.
- Dosing & Administration
Find Dosing & Admin Information
for an R/R FLT3m+ AML Treatment.
- Request a Representative
Request a Rep to Learn More About
a Treatment for R/R FLT3m+ AML.
- Safety Information
View Important Safety Information
for a R/R FLT3m+ AML Treatment.
- Safety Profile
View Adverse Reactions and Safety
Profile of a FLT3m+ AML Treatment.
- Patient Support Programs
Discover Programs to Help Patients
Access an R/R FLT3m+ AML Treatment.
- About FLT3m+ AML
Search results
Boy who died at 15 to become first millennial saint in Catholic Church: What did he do?
WJZY via Yahoo News· 4 days agoHe had also considered priesthood, his mother said, before becoming sick and dying after a battle...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates PR Newswire SUZHOU, China and ROCKVILLE, Md., May 23, 2024 SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma
Swiss National Bank Trims Stake in Kura Oncology, Inc. (NASDAQ:KURA)
ETF DAILY NEWS· 9 hours agoSwiss National Bank trimmed its stake in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 16.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission ...
In the news | Arkansas Democrat Gazette
Arkansas Democrat-Gazette· 6 days agoAsma Assad, wife of Syrian President Bashar Assad, was diagnosed with acute myeloid leukemia -- an aggressive cancer of the bone marrow ...
Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com
ETF DAILY NEWS· 1 day agoStockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the stock ...
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com
ETF DAILY NEWS· 5 days agoStockNews.com assumed coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock ...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 5 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Assetmark Inc. Boosts Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)
ETF DAILY NEWS· 2 days agoAssetmark Inc. boosted its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE – Free Report) by 13.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange ...
Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives $25.60 Consensus Target Price from...
ETF DAILY NEWS· 4 days agoShares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) have earned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat ...
Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $27.94
ETF DAILY NEWS· 6 days agoKura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports.